Find Clinical Trials

Inclusion Criteria: 1. Males and females of age more than equal to 30 years and less than equal to 70 years. 2. Body mass index within 30 kg/m2 and 35 kg/m2 (both values included) with waist circumference above 40 inches (men) or 35 inches (women). 3. Cohort 1 (Only for prediabetes individuals)- Individuals diagnosed with prediabetes with OGTT (140 mg/dL to 199 mg/dL); HbA1c (5.7% to 6.9%) and fasting blood glucose level (between 100 mg/dL to 125 mg/dL). 4. Cohort 2 (T2DM)- Individuals newly diagnosed with Type 2 diabetes mellitus with HbA1c between 7% and 9% (both values included) and fasting blood glucose level in between 126 to 180 mg/dL. 5. Triglycerides between 150 mg/dL and 299 mg/dL (both values inclusive) and/or Low-Density Lipoprotein (LDL) in between 130 mg/dL and 189 mg/dL (both values inclusive). 6. Individuals having non-vegetarian diet for at least 2 days a week. 7. Non-smoker. 8. Individuals who are willing to not change their physical activity levels throughout the study period. 9. Individuals willing to complete all study-related questionnaires and to complete all clinical study visits. 10. Individuals ready to give voluntary, written informed consent to participate in the study. Exclusion Criteria: 1. Individuals who are exclusively vegetarians diet. 2. Individuals with Type 1 diabetes mellitus. 3. Individuals with Type 2 diabetes mellitus on medication. 4. Individuals with any other endocrine disorder. 5. Individuals who are currently on diuretics or thyroid supplements 6. Individuals on lipid-lowering therapies. 7. Individuals with uncontrolled hypertenstion as assessed by systolic over diastolic blood pressure (≥ 140/90 mmHg). 8. Individuals who are currently on antihypertensive medication. 9. Individuals with cardiac arrhythmia, impaired hepatic or renal function 10. Individuals having heart failure, coronary artery disease, hyperthyroidism, hypothyroidism, cancer or mental disease or any other serious disease requiring active treatment. 11. History of malignancy or stroke. 12. Chronic alcoholism: History and/or current cases of chronic alcohol consumption or heavy drinkers as defined by i.For men consuming more than 4 drinks on any day or more than 14 drinks/week ii. For women, consuming more than 3 drinks on any day or more than 7 drinks/week 13. Individuals taking concomitant medication known to alter blood sugar. 14. Individuals having treatment with herbal or any other supplements. 15. Any condition or abnormality that would compromise the safety of the individuals or the quality of the study data. 16. Use of another investigational product within 3 months of the screening visit. 17. Females who are lactating, pregnant or planning to be pregnant or taking any oral contraceptives

Inclusion Criteria: 1. PMDD diagnosis according to DSM-5 2. Menstrual cycle length between 23-34 days, i.e., 5-8 cycles in the last six months 3. Sufficient proficiency in Swedish to comprehend the treatment materials 4. Access to computer/tablet/mobile phone with internet connection Exclusion Criteria: 1. Breastfeeding or pregnancy during the previous three months 2. Initiation of or change in treatment with antidepressants, benzodiazepines, contraceptives, or hormones during the last three months 3. Current or history of a gynaecological disease (e.g., endometriosis, polycystic ovary syndrome) that may confound the results 4. Ongoing or previous psychological treatment for premenstrual disorders 5. Severe mental disorders that may interfere with the person's ability to complete the treatment or complicate the interpretation of results, e.g., psychosis, bipolar disorder, severe eating disorder, or severe depression 6. Elevated suicide risk (e.g., recurrent active suicidal ideation, current suicide plans, previous suicide attempts).

Inclusion Criteria: * Patients must have histologically confirmed invasive breast cancer with metastatic disease * Patients must be candidates for treatment with PARP inhibitor as a single agent or for PARP inhibitor in combination with an ICI per treating physician discretion * Patients must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or magnetic resonance imaging \[MRI\]) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Age \>= 18 years * Karnofsky performance status (KPS) \>= 50% or Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Archival tissue (formalin-fixed paraffin-embedded \[FFPE\]) from at least one metastatic site biopsy should be available prior to study enrollment; if archival tissue is not available, then a metastatic site biopsy will be required during the study screening period * Patient must be willing to proceed with an on-treatment biopsy of metastatic site if an on-treatment \[18F\]FTT PET will be performed (at 12 ± 4 weeks after starting PARP inhibitor ± ICI treatment) * For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to \[18F\]FTT PET imaging on day 1. For women who obtain on-treatment (12-week) \[18F\]FTT imaging, a negative serum pregnancy test will be required within 7 days prior to \[18F\]FTT PET imaging * Men and women of reproductive potential need to agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations * Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures Exclusion Criteria: * Patients with prior myelodysplastic syndrome or acute myeloid leukemia due to rare risk associated with PARP inhibitor therapy * Pregnant or breastfeeding women * Patient with a known hypersensitivity to the proposed PARP inhibitor product * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of PARP inhibitor therapy (per investigator's discretion)

Inclusion Criteria: * Age 12 to 75 years, weight ≥ 40 kg, diagnosed with asthma for at least 12 months； * Currently receiving medium- to high-dose inhaled corticosteroids (ICS) in combination with 1 or 2 control medications and have been on a stable dose for at least 28 days prior to randomization； * Pre-bronchodilator (trough) FEV1 ≤ 80% of predicted normal for adults and ≤90% of predicted normal for adolescents ； * Positive bronchodilator response within 12 months prior to randomization or during the screening period; * Asthma Control Questionnaire (ACQ-5) score ≥ 1.5; * At least one severe asthma exacerbation within 12 months prior to the screening visit and no occurrence within 28 days prior to randomization; * Based on the investigator judgment, the subject demonstrates acceptable inhaler, peak flow meter, and spirometry techniques; * Compliance with usual asthma controller use ≥ 80% based on the patient diary in 7 days prior to dosing; * Voluntarily participate in this clinical study and sign the informed consent form and be able to comply with the clinical visit schedule and study-related procedures; * Female subjects of childbearing potential who are sexually active with non-sterilized male partners, male subjects, and their female partners of childbearing potential agree to use adequate and effective contraception throughout the study; Exclusion Criteria: * Current respiratory disease that may impair lung function as judged by the investigator; * Diagnosis of helminth parasitic infection within 24 weeks prior to randomization and who have not received or have not responded to standard therapy; * Within 28 days prior to randomization, with acute or chronic infection; or have a severe viral infection; * Has a known or suspected history of immunosuppression or frequent, recurrent, or long-term infection; * History of active tuberculosis; or untreated latent tuberculosis or tuberculosis not receiving standard treatment, unless the investigator judges that the patient has been adequately treated; * People with hepatitis B, hepatitis C, or HIV infection; * History of malignancy; * Major surgery within 8 weeks prior to signing the informed; * Bronchial thermoplasty within 12 months prior to randomization; * Treatment of systemic glucocorticoid during 4 weeks prior to signing informed to randomization; * Previous use or ongoing use of systemic immunosuppressants or biologics for the treatment of autoimmune or inflammatory diseases in 8 weeks or 5 half-lives prior to randomization; * Within 16 weeks or 5 half-lives prior to randomization, received a biologic agent with the same therapeutic purpose; * Participated in an interventional clinical trial of any drug or medical device within 3 months or 5 half-lives prior to randomization; * Poor response to or intolerance to prior anti-IL-4Rα antibody therapy; * Within 3 months prior to randomization, received specific immunotherapy； * Receipt of intravenous human immunoglobulin (IVIG) or blood products within 30 days prior to randomization; * Vaccination with live(attenuated) vaccine within 30 days prior to randomization or plan to receive live (attenuated) vaccine during the study; * Are using concomitant medications or treatments that are prohibited in the protocol; * The following laboratory abnormalities occurred during the screening period: eosinophils≥1500 cells/mm3 or 1.5×109/L; Platelets≤80,000 cells/mm3 or 80×109/L; phosphocreatine kinase (CPK) ≥5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) ≥3-fold ULN; aspartate aminotransferase (AST)≥ 3-fold ULN; Bilirubin ≥ 2x ULN; * History of alcohol abuse or drug abuse within 12 months prior to randomization; * Current smokers, or those who have been smoking in recent 6 months, or former smokers who have not been smoking for 6 months with a smoking history of ≥10 pack years; * Allergy to L-histidine, trehalose, or Tween 80, or history of systemic hypersensitivity to any biologic products; * Females of childbearing potential have a positive pregnancy test result during the screening period; Females planning to become pregnant or breastfeeding; * Any clinically significant examination abnormality or serious and/or uncontrolled disease that, in the opinion of the investigator, may affect the subject safety, or affect the evaluation of efficacy, or preclude the subject completion of the entire study.

Inclusion Criteria: * A primary DSM-5 diagnosis of depressive or anxiety disorder * At least two unsuccessful attempts of pharmacological or psychological treatment according to the German guidelines for the treatment of depression or anxiety disorders (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) * Age 18-65 years * Sufficient knowledge of the German language * Participating patients are not required to discontinue medication, but to keep medication constant over the treatment period Exclusion Criteria: * Increased suicidality * Substance abuse or dependency * Borderline personality disorder * Pervasive developmental disorder * Psychotic disorder * Eating disorder * Bipolar disorder * Severe physical illness

Inclusion Criteria: Individuals who are: * Aged 60 years old and above (by year of age) * Able to understand English and/or Mandarin, and * Able to engage in the group drumming activity conducted (e.g. capable of light exercises while seated) Exclusion Criteria: Individuals who are: * On palliative care, and/or * Bed-bound * Have severe hearing impairment such that they are unable to engage in group drumming sessions

Inclusion Criteria: 1. Age 8-70 years 2. Ability to perform spirometry and oscillometry 3. Signed informed consent (and assent for children as appropriate) 4. No respiratory or other major disease (for healthy controls), or physician-diagnosed asthma, COPD, CF, or other airway diseases Exclusion Criteria: 1. Inability or unwillingness to perform AWARE, spirometry, or oscillometry 2. Acute or chronic illness that, at the judgement of investigators, may affect lung function and alter the results of AWARE or the reference PFTs (spirometry and AOS)

Inclusion Criteria: * Consent: Be willing and able to provide written informed consent for the trial. * Age: Male or Female patients aged 18 years or older. * Breast Cancer Diagnosis: Have hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer previously diagnosed by biopsy. HR status is defined as estrogen receptor (ER) \>10% and/or progesterone receptor (PR) \>10%; HER2 status is defined as immunohistochemistry (IHC) 0 or 1+ or IHC 2+, fluorescence in situ hybridization (FISH) negative. * Stage: Have previously untreated early-stage, clinical or anatomic stage I, II, or III hormone receptor-positive breast cancer. * Definitive Treatment: Have had definitive treatment with curative intent for breast cancer, including surgery, chemotherapy, and radiotherapy as indicated. * Body Mass Index (BMI): Have a BMI of 30 kg/m² or more, or a BMI of 27 kg/m² or more with one weight-related complication (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). * Performance Status: Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Cardiac Function: Have a left ventricular ejection fraction (LVEF) of 50% or greater, or greater than the institution's lower limit of normal (LLN), as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening. * Organ Function: Demonstrate adequate organ function in screening labs. * Tumor Specimens: Have archived biopsy or surgical tumor specimens available as tumor blocks or unstained slides. Exclusion Criteria: * Other Clinical Studies: Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. * Stage IV Breast Cancer: Have stage IV, metastatic breast cancer. * Cancer Type: Have HER2-positive or triple-negative breast cancer. * Active Malignancy: Have a concomitant active malignancy. * Performance Status: Have an Eastern Cooperative Oncology Group (ECOG) performance status greater than 2. * Body Mass Index: Have a BMI of less than 27 kg/m². * Type 1 Diabetes Mellitus: Have type 1 diabetes mellitus. * Gastric Emptying Abnormality: Have a known clinically important gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically took drugs that directly affect gastrointestinal motility.

Recruitment for the study will occur at 8 clinic/community sites (Figure 5), each enrolling 40 participants, inclu-sion criteria: (a) live in Alaska, (b) speak English, and (c) be between 14-26 years old, (d) have access to a smart phone or computer to self-administer surveys and access MBAL tool. Exclusion criteria include insufficient cognitive abilities to consent and previous use of the tool. During the initial phase (Weeks 0-4), participants are recruited across all 8 sites, and pre-intervention surveys are administered to all recruited participants. Recruit-ment will continue as needed at each site throughout the study, ensuring that new recruits complete the pre-intervention survey before receiving access to MBAL.

Key inclusion criteria: * Participant must be aged 18 to 75 years of age. * Documented diagnosis of asthma at least 12 months prior to Screening. * Participants must be on maintenance asthma medications, for at least 3 months prior to screening: inhaled corticosteroid (ICS) in combination with long-acting beta agonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist \[LAMA\]). * Participant has an ACQ-6 score ≥1.5 at Screening Visit. * Participant has FEV1 of ≥50% to 90%, inclusive, of predicted normal value at Screening Visit 1. * Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL over the pre-salbutamol FEV1 at Screening Visit. Key exclusion criteria: * Female participant who is pregnant or breastfeeding. * Participant is a current smoker, or former smoker with a smoking history of ≥10 pack-years. * Participant has a known hypersensitivity to any component of the formulation of solrikitug, including any of the excipients, or a history of anaphylactic reaction to any therapeutic monoclonal antibody. * Participant has history or evidence of any clinically significant cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy, or any other condition (risks factors of pneumonia) that in the opinion of the Investigator might obfuscate the study data. * Participant has an exacerbation of asthma requiring use of OCS or hospitalization in the 6 weeks prior to Screening or during the Screening Period. * Participant has history or evidence of any clinically significant pulmonary condition, other than asthma. * Lower respiratory tract infection within the 6 weeks prior to Screening.

Inclusion Criteria: 1. Diagnosis of type 2 diabetes mellitus according to the International Diabetes Guidelines: fasting blood glucose (FBG) ≥ 126 mg/dl (7.0 mmol/l) or 2-hour postprandial blood glucose ≥ 200 mg/dL (11.1 mmol/l), or HbA1c ≥ 6.5% (48 mmol/mol). 2. Age between 18 and 80 years old. 3. Untreated patients or those currently receiving regular anti-diabetic medication therapy, including oral hypoglycemic drugs and insulin, with no restrictions on types or doses. 4. Blood glucose levels not effectively controlled in the three months prior to baseline screening: HbA1c between 6.5% and 10.5%. 5. Willingness to comply with dietary control requirements during the study. 6. Voluntary participation and signing of informed consent form. Exclusion Criteria: 1. Type 1 diabetes, gestational diabetes, and special types of diabetes. 2. History of diabetic acute complications, including ketoacidosis, hyperosmolar coma, and lactic acidosis. 3. Pregnant or lactating women, or women planning pregnancy. 4. Allergy history to Pueraria lobata radix. 5. Severe dysfunction of vital organs such as heart, liver, and kidney, malignant tumors, or severe mental disorders. 6. Anticipated poor compliance or language communication impairments. 7. Currently participating in other clinical trials.

Inclusion Criteria: 1. Aged 18-65 2. diagnosed with Schizophrenia, Bipolar Disorder or Major depressive disorder. 3. For Bipolar and Major depressive disorder, Hamilton Depression Rating Scale scores \>8 4. Multimodal 3 T MRI acquisition available (\*) 5. Genetic and serum inflammatory data available, or serum and whole blood available for genotyping and inflammatory markers determination. Exclusion Criteria: 1. Presence of major medical or neurological disorders 2. Alcohol or drugs abuse or dependence 3. Conditions known to alter immune-inflammatory status, such as rheumatic diseases, malignancies, 4. ongoing treatment with drugs acting on the immune system, such as corticosteroids, NSAIDs and other immunomodulatory drugs. 5. Pregnancy or lactating

Inclusion Criteria: 1. Aged 18 years or older. 2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) \> 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks. 3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement. 4. Stable drug regimen of 3 antihypertensive medicines consisting of a reninangiotensin blocker (ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), and a diuretic for 4 weeks at treatment. 5. Willingness and ability to comply with follow-up requirements. 6. Signed informed consent. Exclusion Criteria: 1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff). 2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve). 3. Secondary causes of hypertension. 4. Calculated eGFR \< 30 mL/min/1.73m2. 5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c \> 10%). 6. Requirement for chronic oxygen therapy or mechanical ventilation. 7. Untreated (no CPAP therapy) sleep apnea (AHI \> 15) 8. Morbid obesity, defined as Body Mass Index \>40 kg/m2 or arm circumference 46 cm. 9. Pacemaker and/or implantable defibrillators. 10. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening. 11. Symptomatic carotid artery disease or \> 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound. 12. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery). 13. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support. 14. History of heart failure (NYHA class III-IV). 15. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation if the condition interferes with a consistent measurement of blood pressure. 16. Unexplained syncope in the last 6 months. 17. History of bleeding disorders, thrombocytopenia, hemophilia, or significant anemia (hemoglobin (Hgb) \< 10 g/dl). 18. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy). 19. History of unresolved drug or alcohol use. 20. Active treatment of a psychiatric ailment. 21. Life expectancy of less than 12 months due to other disease. 22. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures. 23. Participation in another clinical study for which follow-up is currently on-going. 24. Women who are pregnant 25. Resting heart rateof \< 45 beats/min s, confirmed at both baseline visits. 26. Baroreflex failure or autonomic neuropathy 27. Symptomatic, uncontrolled bradyarrhythmias 28. Atrioventricular block of any grade 29. Presence of a vagus stimulator 30. Patients who are likely to require magnetic resonance imaging (MRI) of the cervical area 31. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy 32. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia). 33. Likely exposure to diathermy.

Inclusion Criteria: * Female participant in Jackson Heart Study * Willing to be randomized and comply with all aspects of protocol * Willing to be audio-recorded during group sessions. Exclusion Criteria: * Positive cognitive screen (MMSE \<19) * Severe depressive symptoms (CES-D ≥16) * Pregnant or planning to become pregnant in the next 6 months * Current participation in another trial * Arm circumference \>45 cm and \<22 cm

Inclusion Criteria: * able to write and speak English * Stage DCIS/I/II/III breast cancer diagnosis * 3 months from active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment) up to 10 years since completing treatment * ≥3 documented comorbidities by chart review, or taking ≥10 medications, have ≥ 1 hospitalization over the past year, ≥ 2 emergency department visits over the past year, seen by \> 2 specialists over the past year * able to provide consent Exclusion Criteria: * currently on active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment)

Inclusion Criteria: 1. patients with pathologically proved invasive breast carcinoma. 2. Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines. 3. Renal function (eGFR \> 30 mL/minute per 1.73 m2 ) 4. LVEF is more than 50 % 5. Age ≥ 18 and ≤ 60 years old Exclusion Criteria: 1. patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction. 2. Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens 3. pregnant or breastfeeding patients 4. patients receiving any other cardiotoxic agents. 5. Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus. 6. Mediastinal irradiation including heart. 7. Refusal to sign the written informed consent.

Inclusion Criteria: Inclusion criteria for obese IGT population: * Age range from 18 to 65 years old, including both ends; * Meet the waist circumference cut-off point for central obesity diagnosis specified in the "Guidelines for Primary Diagnosis and Treatment of Obesity (2019)"; * Meet the IGT diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020 Edition); * Voluntarily participate in this study and sign an informed consent form. Inclusion criteria for newly diagnosed obese T2DM population: ① Age range from 18 to 65 years old, including both ends; ② Meet the waist circumference cut-off point for central obesity diagnosis specified in the "Guidelines for Primary Diagnosis and Treatment of Obesity (2019)"; ③ Conform to the T2DM diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020 Edition), and the course of disease is less than 3 months; * Voluntarily participate in this study and sign an informed consent form. Inclusion criteria for healthy individuals: * Age range from 18 to 65 years old, including both ends; * Meets the diagnostic criteria for healthy individuals set by WHO; * Voluntarily sign an informed consent form. Inclusion criteria for IGT for high and low-risk obesity: * Age range from 18 to 65 years old, including both ends; * Meet the waist circumference cut-off point for central obesity diagnosis specified in the "Guidelines for Primary Diagnosis and Treatment of Obesity (2019)"; * Meet the IGT diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020 Edition); * After screening the risk prediction model constructed in this study, it belongs to the high-risk and low-risk populations with abnormal glucose tolerance; * Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: Exclusion criteria for obese IGT patients: * The population who have been continuously using hypoglycemic drugs within the past three months; * Type 1 diabetes and type 2 diabetes (T2DM), pregnancy diabetes, secondary diabetes and other special types of diabetes; * Hyperthyroidism or hypothyroidism caused by endocrine disorders, with poor disease control; * Difficult to control hypertension/hypotension: systolic blood pressure ≥ 200mmHg or diastolic blood pressure ≥ 110mmHg; Or systolic blood pressure ≤ 90mmHg or diastolic blood pressure ≤ 60mmHg; * When screening, patients with various acute infections, or those accompanied by severe infections, severe anemia, or neutropenia; * Accompanied by other major diseases, such as active or untreated malignant tumors, or clinical remission of malignant tumors for less than 5 years; * Organic heart disease, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, with NYHA heart function grading\>Grade III; ⑧ The patient has suffered from any of the following diseases within the past 6 months: coronary intervention (such as CABG or PTCA), stroke (including ischemic and hemorrhagic stroke); ⑨ Severe liver and kidney dysfunction (ALT greater than 3 times the upper normal limit, creatinine greater than 132 μ mol/l); ⑩ Fasting TG\>5.6mmol/L; ⑪ Pregnant and lactating women, as well as women of childbearing age who have not taken effective contraceptive measures; ⑫ Participating in any other clinical trials/researchers; ⑬ Patients with a history of alcoholism or long-term drug abuse; ⑭ Individuals with a history of mental illness are unable to cooperate with the researchers; ⑮ For any other reason, the researcher considers it unsuitable to participate in this study. Exclusion criteria for newly diagnosed obese T2DM patients: * Type 1 diabetes, gestational diabetes, secondary diabetes and other special types of diabetes; * The population who have been continuously using hypoglycemic drugs within the past three months; * Patients with complications of diabetes; * Hyperthyroidism or hypothyroidism caused by endocrine disorders, with poor disease control; * Difficult to control hypertension/hypotension: systolic blood pressure ≥ 200mmHg or diastolic blood pressure ≥ 110mmHg; Or systolic blood pressure ≤ 90mmHg or diastolic blood pressure ≤ 60mmHg; * When screening, patients with various acute infections, or those accompanied by severe infections, severe anemia, or neutropenia; * Accompanied by other major diseases, such as active or untreated malignant tumors, or clinical remission of malignant tumors for less than 5 years; ⑦ Organic heart disease, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, with NYHA heart function grading\>Grade III; ⑧ The patient has suffered from any of the following diseases within the past 6 months: coronary intervention (such as CABG or PTCA), stroke (including ischemic and hemorrhagic stroke); ⑨ Severe liver and kidney dysfunction (ALT greater than 3 times the upper normal limit, creatinine greater than 132 μ mol/l); ⑩ Fasting TG\>5.6mmol/L; * Pregnant and lactating women, as well as women of childbearing age who have not taken effective contraceptive measures; * Patients with a history of alcoholism or long-term drug abuse; * Individuals with a history of mental illness are unable to cooperate with the researchers; * Participating in any other clinical trials/researchers; ⑮ For any other reason, the researcher considers it unsuitable to participate in this study. Exclusion criteria for healthy individuals: * Any history of chronic diseases of various systems that have been previously diagnosed, such as obesity, endocrine and metabolic diseases, hematopoietic system diseases, respiratory system diseases, cardiovascular system diseases, malignant tumors, liver and kidney dysfunction, etc; * When screening, patients with various acute infections, or those accompanied by severe infections, severe anemia, or neutropenia; * Patients with a history of alcoholism or long-term drug abuse; * Pregnant or lactating women; * Individuals with a history of mental illness who cannot cooperate with the research process;

Inclusion Criteria: * Major subject (≥ 18 years old) * Subject with diagnosed bipolar disorder followed on an outpatient basis, in a day hospital or outside the hospital during the period from January 1, 2022 to February 29, 2024. * Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes. Exclusion Criteria: * Subject having expressed his opposition to the reuse of his data for scientific research purposes. * Judicial measures: care under constraint or patient deprived of liberty due to a legal measure

Inclusion Criteria: Current diagnosis of Major Depressive Disorder (MDD), with a depressive episode lasting ≥ 60 consecutive days at the time of screening, as confirmed by structured clinical interview Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject. Exclusion Criteria: History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results (e.g., bipolar disorder, psychosis, seizure disorder, or cardiovascular disease). Known family history of a psychotic disorder (e.g., schizophrenia or schizoaffective disorder) in a first-degree relative (biological parent, full sibling, or child). Current active suicidal ideation with a specific plan within the prior 2 weeks, as assessed via clinical interview and validated instrument (e.g., C-SSRS). Suicide attempt within the prior 6 months, regardless of intent or lethality. Current diagnosis of a substance use disorder Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician). Unwilling or unable to discontinue prescription psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, lithium, anticonvulsants, or mood stabilizers) for the duration of study participation, including any necessary washout period as determined by the investigator. Any condition, finding, or behavior (including suspected deception or noncompliance) that, in the opinion of the investigator, renders the participant unsuitable for the study or likely to interfere with the integrity of the data or safety of the subject.

Inclusion Criteria: * Recently diagnosed with stage I-III breast cancer * Treatments predisposing to cardiotoxicity (anthracyclines, targeted therapies, radiotherapy) * Signed informed consent form * Medical authorisation to participate * Smartphone user level Exclusion Criteria: * Patient underwent previous cancer treatments. * Patients were previously diagnosed with cancer * Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake \>or = to 150 moderate-intensity or 75 min of vigorous-intensity a day * Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis \>70%, metastasis etc.).